Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial CohortEmma Smith, Steven Grinspoon, Roger Bedimo et al.|Open Forum Infectious Diseases|2025Cited by 9
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J. Corley, Steven Grinspoon, Maya Watanabe et al.|Clinical Infectious Diseases|2025Cited by 8
Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With HIVSteven Grinspoon, Markella V. Zanni, Maya Watanabe et al.|Clinical Infectious Diseases|2025Cited by 7
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysisCarl J. Fichtenbaum, Carlos Malvestutto, Maya Watanabe et al.|The Lancet HIV|2025Cited by 7
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S. Bloomfield, Pamela S. Douglas, Maya Watanabe et al.|Circulation Heart Failure|2025Cited by 2